INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,737 | -55.9% | 52,549 | -46.4% | 0.00% | -50.0% |
| Q2 2023 | $6,206 | +42.8% | 98,010 | +22.1% | 0.01% | +33.3% |
| Q1 2023 | $4,346 | -40.0% | 80,253 | -41.3% | 0.01% | -40.0% |
| Q4 2022 | $7,240 | -99.9% | 136,815 | +9.2% | 0.01% | +25.0% |
| Q3 2022 | $5,827,000 | -44.0% | 125,234 | -31.3% | 0.01% | -42.9% |
| Q2 2022 | $10,401,000 | -2.4% | 182,211 | +4.7% | 0.01% | +27.3% |
| Q1 2022 | $10,654,000 | +95.2% | 174,113 | +67.0% | 0.01% | +120.0% |
| Q4 2021 | $5,457,000 | +40.2% | 104,268 | -0.1% | 0.01% | +25.0% |
| Q3 2021 | $3,891,000 | +2.6% | 104,380 | +12.4% | 0.00% | 0.0% |
| Q2 2021 | $3,791,000 | +41.8% | 92,859 | +17.9% | 0.00% | +33.3% |
| Q1 2021 | $2,673,000 | +5.9% | 78,793 | -0.7% | 0.00% | 0.0% |
| Q4 2020 | $2,524,000 | +34.0% | 79,380 | +8.1% | 0.00% | +50.0% |
| Q3 2020 | $1,884,000 | +42.2% | 73,410 | +42.3% | 0.00% | 0.0% |
| Q2 2020 | $1,325,000 | +109.3% | 51,600 | +25.2% | 0.00% | +100.0% |
| Q1 2020 | $633,000 | -55.2% | 41,200 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $1,414,000 | +331.1% | 41,200 | -6.2% | 0.00% | – |
| Q3 2019 | $328,000 | -42.5% | 43,900 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $570,000 | +6.5% | 43,900 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $535,000 | +7.0% | 43,900 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $500,000 | -55.0% | 43,900 | -14.3% | 0.00% | 0.0% |
| Q3 2018 | $1,111,000 | +22.8% | 51,200 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $905,000 | -5.9% | 51,200 | +12.0% | 0.00% | 0.0% |
| Q1 2018 | $962,000 | +86.1% | 45,700 | +28.0% | 0.00% | 0.0% |
| Q4 2017 | $517,000 | -8.2% | 35,700 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $563,000 | +27.1% | 35,700 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $443,000 | -23.6% | 35,700 | -0.0% | 0.00% | 0.0% |
| Q1 2017 | $580,000 | +7.6% | 35,701 | +0.0% | 0.00% | 0.0% |
| Q4 2016 | $539,000 | -7.7% | 35,700 | -6.9% | 0.00% | 0.0% |
| Q3 2016 | $584,000 | -48.9% | 38,344 | +30.2% | 0.00% | -50.0% |
| Q2 2016 | $1,143,000 | -6.9% | 29,451 | -33.3% | 0.00% | 0.0% |
| Q1 2016 | $1,228,000 | -14.2% | 44,159 | +66.0% | 0.00% | 0.0% |
| Q4 2015 | $1,431,000 | +71.8% | 26,600 | +27.9% | 0.00% | +100.0% |
| Q3 2015 | $833,000 | +17.8% | 20,800 | -6.0% | 0.00% | 0.0% |
| Q2 2015 | $707,000 | – | 22,133 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |